- Home
- CFFN vs RIGL Comparison
CFFN vs RIGL Comparison
Compare CFFN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFFN | RIGL |
|---|---|---|
| Founded | 1893 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 911.8M |
| IPO Year | 2010 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CFFN | RIGL |
|---|---|---|
| Price | $8.45 | $40.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.50 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 1.1M | 180.6K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | 79.31 | ★ 1867.68 |
| EPS | 0.51 | ★ 1.97 |
| Revenue | $16,300,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $7.98 | $3.89 |
| Revenue Next Year | $4.98 | $21.95 |
| P/E Ratio | ★ $17.22 | $38.86 |
| Revenue Growth | 6.54 | ★ 64.15 |
| 52 Week Low | $6.07 | $24.84 |
| 52 Week High | $9.26 | $52.61 |
Technical Indicators
Market Signals| Indicator | CFFN | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 31.05 |
| Support Level | $8.43 | $33.93 |
| Resistance Level | $8.83 | $43.74 |
| Average True Range (ATR) | 0.21 | 2.29 |
| MACD | 0.03 | -0.77 |
| Stochastic Oscillator | 47.21 | 18.56 |
Price Performance
Historical ComparisonAbout CFFN Capitol Federal Financial Inc.
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.